NCT02675127View on ClinicalTrials.gov

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Healthy

Interventions

DRUG

Daktavira

1 tablet contains 60 mg Daclatasvir

DRUG

Daklinza

1 tablet contains 60 mg Daclatasvir

Trial Locations (1)

11757

Genuine Research Center GRC, Cairo

All Listed Sponsors

collaborator

European Egyptian Pharmaceutical Industries

INDUSTRY

lead

Genuine Research Center, Egypt

INDUSTRY

NCT02675127 - Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK) | Biotech Hunter | Biotech Hunter